ADAM Metallopeptidase Domain 33 (ADAM33) ELISA Kits

Mouse (Murine) ADAM Metallopeptidase Domain 33 (ADAM33) interaction partners

1. The mouse and human predicted proteins consisted of 797 and 813 amino acids, respectively, and they shared 70% homology of the entire amino acid sequence.

2. Identification and preliminary characterization of mouse Adam33.

3. ADAM33 is not essential for growth or reproduction in the mouse and does not modulate baseline or allergen-induced airway responsiveness.

4. Adam33/Adam33 shows 2 significant increments in expression during lung morphogenesis, suggesting important developmental regulation.

Xenopus laevis ADAM Metallopeptidase Domain 33 (ADAM33) interaction partners

1. Here, the authors show that adam13 interacts with the arid3a/dril1/Bright transcription factor. This interaction promotes a proteolytic cleavage of arid3a and its translocation to the nucleus where it regulates another transcription factor: tfap2alpha. Tfap2alpha in turn activates multiple genes including the protocadherin pcdh8l (PCNS).

2. Increased ADAM13 cleavage of cadherin 11produces the EC1-3 fragment which increases cranial neural crest cell invasiveness in vitro and blocks the repulsive contact inhibition of locomotion response in colliding cells.

3. Novel roles for Plk and GSK3 regulation of ADAM13 function in cranial neural crest cell migration.

4. Data show that ADAM13 function is autonomous to cranial neural crest (CNC) tissue.

5. The cytoplasmic domain of ADAM13 regulates the expression of multiple genes in cranial neural crest, including the protease Calpain8-a.

Human ADAM Metallopeptidase Domain 33 (ADAM33) interaction partners

1. In a case-control study ADAM33 rs678881 polymorphism significantly increased the risk of childhood asthma in Chinese Han population, but not rs2280089 or rs2853209.

2. ADAM33 F+1 mutant gene A may increase the risk of chronic obstructive pulmonary disease among the Asian population, while it may not associate with the European population

3. Studies show alleles and genotypes of T2, Q1 and F + 1 polymorphisms in ADAM33 gene associate with asthma susceptibility among Asian populations, while V4 polymorphism associates with asthma among Caucasian populations

4. we failed to show association between any genotype and allele of T1 and V4 SNPs in ADAM33 gene with susceptibility to asthma.

5. IFN-gamma may participate in airway remodeling in asthma by downregulating the expression of the ADAM33 gene.

6. This study suggests that metabolites of phthalate such as MEHHP, MECPP, MEOHP and Sigma4MEHP may increase the intron 1 methylation level to elevate ADAM33 gene expression and have a protective effect on reducing the risk of breast cancer.

7. There was no significant difference in ADAM33 genotype and allele distributions between psoriasis and control groups (p > 0.05). CONCLUSIONS: ADAM33 V4 C/G rs2787094 polymorphism was not associated with psoriasis risk in the Turkish population.

8. A lower level of ADAM33 was also correlated with shorter overall survival and metastasis-free survival and was considered an independent prognostic factor suggesting that ADAM33 is a novel molecular biomarker of Triple-negative breast cancer and basal-like phenotype that might be useful as a prognostic factor.

9. IL4RA and ADAM33 variants may be risk markers of asthma exacerbations in type-2 inflammatory endotype. Precise endotyping may facilitate the identification of genetic risk markers of asthma exacerbations.

10. Collectively, our findings suggest that 1,25(OH)2D3 inhibits VEGF-induced ASM cell proliferation by suppressing VEGFR2 and ERK1/2 activation and downregulating ADAM33. Further studies of these mechanisms are needed to facilitate the development of treatments for smooth muscle hyperplasia-associated diseases of the airway such as asthma.

11. meta-analysis suggested that ADAM33 polymorphisms rs2280091, rs2280090, rs2787094, rs44707 and rs528557 were significantly associated with a high risk of childhood asthma

12. There was a significant difference in the frequency of ADAM33 V4 polymorphism in both, asthmatic and COPD patients groups. No significant differences were found for T1 polymorphism. However, there were significant differences when haplotypes and diplotypes of ADAM33 V4/T1 were compared in all three groups. It can be concluded that the polymorphism V4 of ADAM33 is associated with asthma or COPD in Venezuelan patients.

13. Evidence from this meta-analysis demonstrates that ADAM33 T1 polymorphism might be associated with increased susceptibility to asthma among Asian children and that ADAM33 F + 1, T2, S2, or V4 polymorphism may be unrelated to susceptibility of childhood asthma.

14. enhances ADAM-33 expression and airway smooth muscle cell proliferation

15. An association between ADAM33 gene polymorphism and impaired lung functions was detected in wood dust-exposed workers.

16. This meta-analysis demonstrates that the ADAM33 gene polymorphisms confer susceptibility to allergic rhinitis

17. findings suggest that genetic variants of ADAM33 gene may play important roles in asthma susceptibility in the Punjabi population of Pakistan

18. We investigated the influence of ADAM33 polymorphisms on the serum levels of ADAM33 and the susceptibility to pediatric asthma in the Chinese Han population

19. ADAM33 and ADAM12 genetic polymorphisms and their expression in Egyptian children with asthma

20. the ADAM33 T1, T2, S1, Q-1, F+1 and ST+5 six locus polymorphisms association with the risk of COPD.